Mark Hopman Sells 868 Shares of Beta Bionics, Inc. (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 868 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $15,528.52. Following the transaction, the insider now owns 34,132 shares in the company, valued at approximately $610,621.48. This trade represents a 2.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Beta Bionics Stock Performance

Shares of BBNX opened at $19.55 on Friday. The firm’s 50-day moving average price is $12.90. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $24.50.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.01).

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BBNX. Lake Street Capital began coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $30.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Beta Bionics in a report on Friday, May 30th. They set a “neutral” rating and a $16.00 price target for the company. Stifel Nicolaus started coverage on Beta Bionics in a research note on Monday, February 24th. They issued a “buy” rating and a $25.00 price objective on the stock. Leerink Partnrs raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 24th. Finally, Leerink Partners started coverage on Beta Bionics in a research note on Monday, February 24th. They set an “outperform” rating and a $28.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average price target of $23.13.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of BBNX. Strs Ohio bought a new position in shares of Beta Bionics during the 1st quarter worth about $29,000. Corebridge Financial Inc. bought a new stake in Beta Bionics in the first quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Beta Bionics in the first quarter worth about $95,000. MetLife Investment Management LLC bought a new position in Beta Bionics during the first quarter worth about $102,000. Finally, Deutsche Bank AG bought a new position in Beta Bionics during the first quarter worth about $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.